Dr. William Boudouris, board-certified neurologist at Michigan Institute for Neurological Disorders (MIND), recently spoke with ClickOnDetroit’s WDIV-TV Local 4’s Nick Monacelli in an interview about a newly FDA-approved blood test that could transform how Alzheimer’s is detected.
The new blood test will increase opportunities for early detection and treatment. It identifies amyloid (an abnormal protein linked to Alzheimer’s) and is now clear for use in adults who are 55 and older who are experiencing early signs of cognitive decline.
Dr. Boudouris explained that this marks a major step toward more accessible and less invasive Alzheimer’s screening. “This is really groundbreaking information with this lab test. Hopefully we will continue to see more development of biomarkers to be able to screen people with this blood test will be very helpful,” said Dr. Boudouris.
At MIND, Dr. Boudouris and the expert neurology team provide the latest evidence-based care to patients living with Alzheimer’s disease and other memory disorders.